Oxurion To Participate in Upcoming Scientific and Investor Conferences
September 12 2022 - 1:00PM
Oxurion To Participate in Upcoming Scientific and Investor
Conferences
Leuven, BELGIUM, Boston, MA, US
– September
12, 2022
– 7.00 PM CET – Oxurion NV (Euronext
Brussels: OXUR) a biopharmaceutical company developing next
generation standard of care ophthalmic therapies, with clinical
stage assets in vascular retinal disorders, announced that it will
participate in two upcoming conferences.
American Academy of Ophthalmology (AAO) 2022 Annual
Meeting – Chicago,
ILDate: Friday - Monday, September 30 - October 3,
2022
Title: “Phase 2 Part A Trial Results of THR-149
in Diabetic Macular Edema Patients with Suboptimal Response to
anti-VEGF Agents” e-poster presented by Rahul Khurana, MD.
BIO-Europe
– Leipzig, Germany Date: Monday -
Wednesday, October 24-26, 2022 Tom Graney, CEO, will be
delivering a presentation and both he and Michaël Dillen, Chief
Business Officer, will be available for one-on-one
meetings.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 16 75 14 69michael.dillen@oxurion.com |
USConway CommunicationsBeth
Kurthbkurth@conwaycommsir.com ICR WestwickeChristopher
BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com |
- OXUR October Conferences 2022.0912
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Apr 2023 to Apr 2024